2-Hydroxy-3-(2-phenylacetyl)benzoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 2-Hydroxy-3-(2-phenylacetyl)benzoic acid
• 化学式: C₁₅H₁₂O₄
• 分子量: 256.25
• InChiKey: ZQKJXMOPIMFIKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] MACROLIDE-CONJUGATES WITH ANTI-INFLAMMATORY ACTIVITY<br/>[FR] CONJUGUES MACROLIDES A ACTIVITE ANTI-INFLAMMATOIRE
  申请人：PLIVA PHARMACEUTICAL INDUSTRY

  公开号：WO2004094449A1

  公开（公告）日：2004-11-04

  The present invention relates to new compounds represented by Formula (I); wherein M represents a macrolide subunit of the substructure II, Formula (II); L represents the chain of the substructure III, Formula (III); D represents the steroid or nonsteroidal subunit derived from steroid or nonsteroidal (NSAID) drugs with anti-inflammatory activity. The present invention relates also to pharmaceutically acceptable salts and solvates of such prepared compounds, to processe and intermediates for their preparation, as well as to the improved therapeutic action and the use in the treatment of inflammatory diseases and conditions in humans and animals.

  本发明涉及由式（I）表示的新化合物；其中M表示亚结构II，式（II）的大环内酯亚基；L表示亚结构III，式（III）的链；D表示从类固醇或非类固醇（NSAID）药物中衍生的类固醇或非类固醇亚基，具有抗炎活性。本发明还涉及制备这些化合物的药学上可接受的盐和溶剂化物，以及用于它们的制备的过程和中间体，以及在人类和动物的炎症性疾病和病况的治疗中的改进治疗作用和用途。
• 9A-SUBSTITUTED AZALIDES FOR THE TREATMENT OF MALARIA
  申请人：Alihodzic Sulejman

  公开号：US20090105301A1

  公开（公告）日：2009-04-23

  The present invention relates to novel 9a-substituted azalides having antimalarial activity. More particularly, the invention relates to 9a-substituted 9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A, 3-O-decladinosyl-9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A and 3-O-decladinosyl-5-O-dedesosaminyl-9a-aza-9-deoxo-9-dihydro-9a-homoerythromycin A compounds having antimalarial activity, to the method of preparation, to the method of use, and to pharmaceutically acceptable derivatives thereof having antimalarial activity.

  本发明涉及具有抗疟活性的新型9a-取代的氮杂环己烷酮类化合物。更具体地说，本发明涉及9a-取代的9a-氮杂-9-去氧-9-二氢-9a-同麻黄霉素A、3-O-去克拉地诺糖基-9a-氮杂-9-去氧-9-二氢-9a-同麻黄霉素A和3-O-去克拉地诺糖基-5-O-去脱氨基-9a-氮杂-9-去氧-9-二氢-9a-同麻黄霉素A化合物的抗疟活性、制备方法、使用方法以及具有抗疟活性的药学上可接受的衍生物。
• Compounds with anti-inflammatory activity
  申请人：GlaxoSmithKline istrazivacki centar Zagreb d.o.o.

  公开号：EP2070940A1

  公开（公告）日：2009-06-17

  The present invention relates to new compounds represented by Formula I: wherein M represents a macrolide subunit of the substructure II: L represents the chain of the substructure III:          -X1-(CH2)m-Q-(CH2)n-X2-     III D represents the steroid or nonsteroidal subunit derived from steroid or nonsteroidal (NSAID) drugs with anti-inflammatory activity; The present invention relates also to pharmaceutically acceptable salts and solvates of such prepared compounds, to processe and intermediates for their preparation, as well as to the improved therapeutic action and the use in the treatment of inflammatory diseases and conditions in humans and animals.

  本发明涉及由式 I 表示的新化合物： 其中 M 代表亚结构 II 的大环内酯亚基： L 代表亚结构 III 的链： -X1-(CH2)m-Q-( )n-X2- III D 代表源自具有抗炎活性的类固醇或非类固醇（NSAID）药物的类固醇或非类固醇亚基； 本发明还涉及此类制备的化合物的药学上可接受的盐和溶液、制备它们的工艺和中间体，以及在治疗人类和动物的炎症性疾病和病症中的改良治疗作用和用途。
• Conjugates with anti-inflammatory activity
  申请人：GlaxoSmithKline istrazivacki centar Zagreb d.o.o.

  公开号：EP2196469A1

  公开（公告）日：2010-06-16

  The present invention relates to new compounds represented by Formula I: wherein M represents a macrolide subunit of the substructure VIII: L represents the chain of the substructure IX or XIII:          -X1-(CH2)m-Q-(CH2)n-X2-     IX          -X1-(CH2)m-V-(CH2)p-Q-(CH2)n-X1-     XIII Z represents the steroid or nonsteroidal subunit derived from steroid or nonsteroidal (NSAID) drugs with anti-inflammatory activity; The present invention relates also to pharmaceutically acceptable salts and solvates of such prepared compounds, to processe and intermediates for their preparation, as well as to the improved therapeutic action and the use in the treatment of inflammatory diseases and conditions in humans and animals.

  本发明涉及由式 I 表示的新化合物： 其中 M 代表子结构 VIII 的大环内酯亚基： L 代表子结构 IX 或 XIII 的链： -X1-(CH2)m-Q-( )n-X2- IX -X1-( )m-V-( )p-Q-( )n-X1- XIII Z 代表从具有抗炎活性的类固醇或非类固醇（NSAID）药物中提取的类固醇或非类固醇亚基； 本发明还涉及此类制备的化合物的药学上可接受的盐和溶液、制备它们的工艺和中间体，以及在治疗人类和动物的炎症性疾病和病症中的改进治疗作用和用途。
• Composition for use in treating and preventing inflammation related disorder
  申请人：Holy Stone Healthcare Co.,Ltd.

  公开号：EP2543357A1

  公开（公告）日：2013-01-09

  The present invention is related to a use for treating and preventing inflammation related disorder of a composition containing a drug and hyaluronic acid (HA) or HA mixture, whereas the HA or the HA mixture as a delivery vehicle can be a formulation including at least two HAs having different average molecular weights. The composition has been demonstrated to be capable of reducing the therapeutic dose of a drug on the treatment and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary disease, coeliac disease, conjunctivitis, otitis, allergic rhinitis, gingivitis, aphthous ulcer, bronchitis, gastroesophageal reflux disease (GERD), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (IBD), Crohn's Disease, irritable bowel syndrome (IBS), intestinal inflammation or allergy, urethritis, cystitis, vaginitis, proctitis, eosinophilic gastroenteritis, or rheumatoid arthritis.

  本发明涉及一种含有药物和透明质酸（HA）或HA混合物的组合物治疗和预防炎症相关疾病的用途，而作为给药载体的HA或HA混合物可以是包括至少两种具有不同平均分子量的HA的制剂。该组合物已被证明能够减少治疗和预防炎症相关疾病的药物治疗剂量，这些疾病包括急性炎症性疾病、慢性阻塞性肺病、乳糜泻、结膜炎、耳炎、过敏性鼻炎、牙龈炎、咽喉溃疡、支气管炎、胃食管炎、溃疡性结膜炎、过敏性鼻炎、牙龈炎、咽喉溃疡、支气管炎、胃食管反流病（GERD）、食管炎、胃炎、肠炎、消化性溃疡、炎症性肠病（IBD）、克罗恩病（Crohn's Disease）、肠易激综合征（IBS）、肠道炎症或过敏、尿道炎、膀胱炎、阴道炎、直肠炎、嗜酸性粒细胞性肠胃炎或类风湿性关节炎。